HIV Vaccine Science Academy

2024 HIV Vaccine Advocacy Academy

Mon, 16 Dec 2024 - Wed, 18 Dec 2024

9:00am - 6:00pm [CET]

Windhoek, Namibia

The 2024 HIV Vaccine Advocacy Academy, organized by the Global HIV Vaccine Enterprise of IAS – the International AIDS Society, will award fellowships to 15 early- to mid-career advocates from central, eastern, southern or western Africa to take part in workshops on HIV vaccine-related advocacy with international experts.   

The 2024 academy will take place in Windhoek, Namibia, on 16-18 December. Selected participants will receive full travel support.   

The deadline for applications is 20 October, 23:59 CEST.  

The objectives are to:  

  • Provide training on basic and HIV-related vaccine research and development. 
  • Provide training on the ability to reach target audiences and adequately communicate relevant needs of and for an HIV vaccine.
  • Provide a unique opportunity to engage and discuss with leaders in the HIV vaccine field, in a retreat-type setting, on building and facilitating collaborations in the advocacy for an HIV vaccine.  
  • Support participants in establishing a sustainable network across different research institutions and creating momentum for African-led vaccine advocacy. 

 To be eligible, applicants should:  

  • Be proficient in English 
  • Be a national and a resident of a central, eastern, southern or western African country 
  • Be affiliated with a central, eastern, southern or western African institution 
  • Have a letter of support from their home organization 
  • Be an advocate or peer educator in the HIV field 
  • Be interested in the latest research developments towards an HIV vaccine 
  • Be affiliated with HIV associations, groups or committees based in countries with limited resources for HIV vaccine research 
  • Be willing, and have a plan, to disseminate the knowledge acquired during the academy in their home institution 

Please contact enterprise@iasociety.org if you have any questions.

Register now

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.